Why Coherus Biosciences Stock Tumbled on Thursday

The final set of results for Coherus Biosciences' (CHRS -5.65%) 2023 was released after market hours on Wednesday, and investors reacted with displeasure the following day. They traded the stock down by more than 6% Thursday, a much steeper fall than the 0.6% dip of the S&P 500 index.Fourth-quarter revenue doubled, but still fell short of estimatesFor the quarter, Coherus -- a busy commercial-stage biotech -- posted net revenue of $91.5 million, slightly more than double the $45.4 million it earned in the s ...